Developing a new vaccine platform to stimulate protective antibodies against HIV-1
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
This study is testing a new type of vaccine that aims to help your body create strong antibodies against HIV-1 by using a special method to present the vaccine ingredients, making it easier for your immune system to respond effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11009908 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine platform designed to elicit broadly neutralizing antibodies (bnAbs) against HIV-1. By administering multiple immunogens in a specific sequence, the approach aims to guide the maturation of these antibodies through common immunologic barriers. The researchers are addressing challenges such as low immunogenicity of the HIV-1 envelope and the need for high-affinity interactions to promote the development of effective antibodies. The use of nanoparticles to enhance the presentation of these immunogens is a key aspect of the methodology.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for HIV infection or those who are HIV-negative but interested in participating in vaccine trials.
Not a fit: Patients who are already HIV-positive or those with severe immune deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that generates protective antibodies in humans.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance antibody responses, but this specific strategy is innovative and largely untested in humans.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Saunders, Kevin O — Duke University
- Study coordinator: Saunders, Kevin O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.